Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02650492 : Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- >18 years of age

- histologically confirmed malignant melanoma

- advanced melanoma disease (Stage III inoperable or Stage IV) that has progressed on
standard first line treatment such as kinase inhibitor(s) and/or immunoregulatory
monoclonal antibodies. Previously untreated patients with a dominant tumour lesion
deemed suitable for local and highly tumour-destructive ablation may also be included

- time interval between previous systemic treatment and imILT of at least one month

- at least one lesion located in such a way (typically subcutaneously) that it can be
treated without risk of skin necrosis or serious damage to other adjacent vital and
healthy tissue

- verbal and written informed consent to participate

- adequate haematologic, renal and hepatic functions

- have an ECOG performance status ? 2 (Karnofsky ? 60%)

Exclusion Criteria:

- known HIV infection

- autoimmune disease which is judged to reduce an anti-tumour immune response

- systemic corticosteroid medication

- bleeding diathesis

- pregnancy or breast-feeding
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557